IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 1-25 out of 1244.

1 | 2 | 3 | 4 | 5 > >>

Public Release: 9-Dec-2016
Journal of the American Medical Informatics Association
Study reveals drug interactions that may reduce mortality in breast cancer patients
Patient health records revealed two drug combinations that may reduce mortality rates in breast cancer patients, according to a study led by researchers at the Stanford University School of Medicine.

Contact: Jennie Dusheck
dusheck@stanford.edu
650-725-5376
Stanford University Medical Center

Public Release: 9-Dec-2016
San Antonio Breast Cancer Symposium
Naturally occurring symptoms may be mistaken for tamoxifen side-effects
Women taking tamoxifen to prevent breast cancer were less likely to continue taking the drug if they suffered nausea and vomiting, according to new data presented at the San Antonio Breast Cancer Symposium.

Contact: Kathryn Ingham
Kathryn.Ingham@cancer.org.uk
020-346-95475
Cancer Research UK

Public Release: 9-Dec-2016
San Antonio Breast Cancer Symposium
Untreated effects of breast cancer care increase depression and anxiety among survivors
For many of the 2.8 million survivors in the United States, the price of survival includes severe physical and psychosocial symptoms -- including joint pain, fatigue, weight gain and insomnia -- that may go untreated and persist for many years after treatment. Long-term survivors report an average three symptoms for which they desire more help than they are receiving, according to new research. Results of the study will be presented on Friday at the 2016 San Antonio Breast Cancer Symposium (poster P5-13-12).

Contact: Katie Delach
katie.delach@uphs.upenn.edu
215-776-6063
University of Pennsylvania School of Medicine

Public Release: 9-Dec-2016
San Antonio Breast Cancer Symposium
Depression drug reduces joint pain for women with early stage breast cancer
A drug typically used to treat depression and anxiety can significantly reduce joint pain in postmenopausal women being treated for early stage breast cancer, according to new SWOG research to be presented Friday at a special plenary presentation at the San Antonio Breast Cancer Symposium.
NIH/National Cancer Institute, Damon Runyon Cancer Research Foundation, Eli Lilly and Company

Contact: Wendy Lawton
lawtonw@ohsu.edu
503-348-8675
SWOG

Public Release: 9-Dec-2016
ACS Chemical Biology
Study provides new focus for developing drugs to fight cancer
Cancer researchers and drug companies may have been too quick to ignore a promising line of inquiry that targets a specific cell protein, according to a research team led by a biomedical scientist in the School of Medicine at the University of California, Riverside.
National Institutes of Health, Chronic Lymphocytic Leukemia Research Consortium, UC San Diego Foundation Blood Cancer Research Fund and Bennett Family Foundation

Contact: Iqbal Pittalwala
iqbal@ucr.edu
951-827-6050
University of California - Riverside

Public Release: 9-Dec-2016
Leukemia
Aggressive form of leukemia linked to defective 'protein factory'
20 to 40 percent of the patients with multiple myeloma -- a type of leukemia -- have a defect in the ribosome, the protein factory of the cell. These patients have a poorer prognosis than patients with intact ribosomes. At the same time, they respond better to a drug that already exists. These are the findings of a study by the Laboratory for Disease Mechanisms in Cancer at KU Leuven (University of Leuven), Belgium.
European Research Council, Research Foundation Flanders, Stichting tegen Kanker, Flemish Government/Innovation by Science and Technology

Contact: Prof. Kim De Keersmaecker
kim.dekeersmaecker@kuleuven.be
32-163-73167
KU Leuven

Public Release: 9-Dec-2016
San Antonio Breast Cancer Symposium
Breast cancer mortality rates decline in many countries
Breast cancer mortality rates continue to decline in many nations, but a review of mortality trends in 47 countries around the world indicates some significant disparities, particularly in South Korea and some Latin American nations, according to results presented at the 2016 San Antonio Breast Cancer Symposium, held Dec. 6-10.
International Prevention Research Institute

Contact: Lauren Riley
lauren.riley@aacr.org
215-446-7155
American Association for Cancer Research

Public Release: 9-Dec-2016
2016 San Antonio Breast Cancer Symposium
Image-guided biopsy identifies patients who achieve pathologic complete response after neoadjuvant therapy
In a pilot study conducted at The University of Texas MD Anderson Cancer Center, image-guided biopsies identified select breast cancer patients who achieved pathologic complete response (pCR) after chemotherapy and/or targeted therapy, neoadjuvant systemic therapy (NST).

Contact: Laura Sussman
lsussman@mdanderson.org
713-745-2457
University of Texas M. D. Anderson Cancer Center

Public Release: 9-Dec-2016
San Antonio Breast Cancer Symposium
EndoPredict outperforms Oncotype Dx in predicting the risk breast cancer recurrence
Data being presented at the 2016 San Antonio Breast Cancer Symposium show Myriad's EndoPredict, a second-generation test, significantly outperformed Oncotype Dx, a first-generation test, in predicting the long-term recurrence of breast cancer, particularly in years five to 10 following surgery. Clinicians can consider using EndoPredict to identify patients who can forgo chemotherapy with confidence, knowing they have a low risk of recurrence over 10 years.

Contact: Ron Rogers
rrogers@myriad.com
908-285-0248
Myriad Genetics, Inc.

Public Release: 9-Dec-2016
BioResearch Open Access
Diet, the gut microbiome, and colorectal cancer: are they linked?
Recent evidence from animal models suggests a role for specific types of intestinal bacteria in the development of colorectal cancer (CRC). If a microbial imbalance in the gut could actively contribute to CRC in humans, dietary-based therapeutic interventions may be able to modify the composition of the gut microbiome to reduce CRC risk, as discussed in a review article published in BioResearch Open Access.

Contact: Kathryn Ryan
kryan@liebertpub.com
914-740-2100
Mary Ann Liebert, Inc./Genetic Engineering News

Public Release: 9-Dec-2016
2016 San Antonio Breast Cancer Symposium
Older women with breast cancer report better cosmetic satisfaction with less radiation, less surgery
In the first study evaluating patient-reported cosmetic outcomes in a population-based cohort of older women with breast cancer, The University of Texas MD Anderson Cancer Center researchers found that less radiation was associated with improved cosmetic satisfaction long-term.

Contact: Laura Sussman
lsussman@mdanderson.org
713-745-2457
University of Texas M. D. Anderson Cancer Center

Public Release: 9-Dec-2016
2016 San Antonio Breast Cancer Symposium
Penn study begins to shed light on racial disparities of cancer-causing genetic mutations
Most studies reporting the prevalence of breast- and ovarian-cancer causing genes have been conducted with Caucasian women, leaving questions about the role that these same genes play in African American patients with inherited cancers. Now, a team led by researchers at the Basser Center for BRCA is showing that cancer-causing mutations present different patterns in African-American women than in Caucasian women. The study will be presented Friday at the 2016 San Antonio Breast Cancer Symposium (poster P5-10-04).

Contact: Katie Delach
katie.delach@uphs.upenn.edu
215-776-6063
University of Pennsylvania School of Medicine

Public Release: 9-Dec-2016
Nature Reviews Cancer
Breast cancer patients could benefit from controversial hormone
An international team of researchers involving the University of Adelaide is tackling the controversy over what some scientists consider to be a 'harmful' hormone, arguing that it could be a game changer in the fight against recurring breast cancers that are resistant to standard treatments.

Contact: Wayne Tilley
wayne.tilley@adelaide.edu.au
University of Adelaide

Public Release: 8-Dec-2016
Molecular Cell
Scientists reveal 'safety catch' within all dividing cells
Researchers have made a major discovery about how cells control when to divide -- representing a step forward in scientists' understanding of one of the most fundamental processes of life.
Cancer Research UK, Wellcome, Science Foundation Ireland, European Union

Contact: Sophia McCully
sophia.mccully@icr.ac.uk
020-735-25136
Institute of Cancer Research

Public Release: 8-Dec-2016
European Journal of Immunology
Localized immunotherapy new possibility to treat bladder cancer
Antibody-based immunotherapy is a new promising method to treat cancer. Unfortunately, today's treatments can result in adverse side effects. New findings from Uppsala University show an alternative way to administer the therapy, which has the same effect on the tumor but less impact other parts of the body.

Contact: Sara Mangsbo
sara.mangsbo@igp.uu.se
46-704-250-878
Uppsala University

Public Release: 8-Dec-2016
Journal of Molecular Diagnostics
DNA methylation biomarker for prostate cancer shows promise for accurately determining patient risk
Report in The Journal of Molecular Diagnostics describes a biomarker, PITX2 DNA methylation, which is capable of distinguishing cancerous tissue from non-cancerous tissue and predicting the risk of cancer recurrence using only small amounts of tissue obtained from core needle biopsies.
University Hospital Bonn

Contact: Eileen Leahy
jmdmedia@elsevier.com
732-238-3628
Elsevier Health Sciences

Public Release: 8-Dec-2016
JAMA Oncology
Tumor found in a 255-million-year-old mammalian ancestor
A tumor in a 255-million-year-old mammalian ancestor called a gorgonopsian is detailed in a new research letter published online by JAMA Oncology.

Contact: James Urton
jurton@uw.edu
206-543-2580
The JAMA Network Journals

Public Release: 8-Dec-2016
Royal Society Interface
Rice scientists' study of human migration could help understand cancer metastasis
A new Rice University study finds that migration for the first humans in America was easier moving east-west as opposed to north-south, largely because the knowledge needed to live in the same climate zones was easily transferable. Researchers said the findings could also shed light on the behavior of metastatic cancers.

Contact: David Ruth
david@rice.edu
713-348-6327
Rice University

Public Release: 8-Dec-2016
JAMA Oncology
Study shows new treatment strategy in head & neck cancer not better than current standard
Results of the largest Canadian clinical trial to date comparing standard treatment for locally advanced squamous cell head and neck cancer with an experimental treatment did not show the new treatment is superior.
Amgen Inc., Canadian Cancer Society Research Institute, The Princess Margaret Cancer Foundation

Contact: Jane Finlayson
jane.finlayson@uhn.ca
416-946-2846
University Health Network

Public Release: 8-Dec-2016
San Antonio Breast Cancer Symposium
UH Seidman cancer center expert presents triple-negative breast cancer immunotherapy trial
A researcher from UH Seidman Cancer Center will discuss his upcoming immunotherapy clinical trial for triple-negative breast cancer at 2016 San Antonio Breast Cancer Symposium. Joseph Baar, MD, PhD, Director of Breast Cancer Research at UH Seidman Cancer Center, will share details about a phase II clinical trial testing the effectiveness of combining carboplatin and nab-paclitaxel with an immunotherapeutic agent called pembrolizumab in patients with metastatic triple-negative breast cancer.

Contact: Alicia Reale
alicia.reale@uhhospitals.org
University Hospitals Cleveland Medical Center

Public Release: 8-Dec-2016
Clinical Cancer Research
Oral bacterium related esophageal cancer prognosis in Japanese patients
A type of bacterium usually found in the human mouth, Fusobacterium nucleatum (F. nucleatum), has been found to be related to the prognosis of esophageal cancer in Japanese patients by researchers from Kumamoto University, Japan. The bacteria are a causative agent of periodontal disease and though it can be found among the intestinal flora, it hasn't been the focus of much research until now.
SGH Foundation

Contact: J. Sanderson
research-coordinator@jimu.kumamoto-u.ac.jp
Kumamoto University

Public Release: 8-Dec-2016
eLife
Researchers identify potentially druggable mutant p53 proteins that promote cancer growth
Scientists have focused on certain p53 mutations that generate mutant proteins that promote cancer growth and metastasis. The variants studied are truncated -- they lack half of the domains, or units, of the full-length p53 protein, which enable full-length p53 to enter the cell nucleus and bind DNA, essential in its normal tumor-suppressor function. The truncated mutants act by perturbing mitochondrial function, the team proposes.
NIH/National Cancer Institute, Swim Across America

Contact: Peter Tarr
tarr@cshl.edu
516-367-5055
Cold Spring Harbor Laboratory

Public Release: 8-Dec-2016
New England Journal of Medicine
Treating cancer, mental health neglect in rural America
OHSU Knight Cancer Institute oncologist publishes New England Journal of Medicine 'Perspective' on her experience treating a patient in rural Oregon with breast cancer, mental illness.

Contact: Amanda Gibbs
gibbam@ohsu.edu
503-758-9069
Oregon Health & Science University

Public Release: 8-Dec-2016
San Antonio Breast Cancer Symposium
Researchers identify biomarkers of response to treatment in invasive breast cancer
Researchers report at the San Antonio Breast Cancer Symposium that they have identified biomarkers they believe can be used as part of a larger model to predict how patients with HER2-positive operative breast cancer will respond to the targeted treatment trastuzumab, commercially known as Herceptin, and chemotherapy.

Contact: Laura Oleniacz
laura_oleniacz@med.unc.edu
919-445-4219
UNC Lineberger Comprehensive Cancer Center

Public Release: 8-Dec-2016
Cancer
Prostate cancer patients more likely to die of other diseases, say 15-year PLCO results
15-year PLCO results published this month in Cancer: 'Most men diagnosed with prostate cancer will not die from their disease... now we need to focus on discovering the men that will,' says E. David Crawford, M.D., investigator at the University of Colorado Cancer Center.

Contact: Garth Sundem
garth.sundem@ucdenver.edu
University of Colorado Anschutz Medical Campus

Showing releases 1-25 out of 1244.

1 | 2 | 3 | 4 | 5 > >>

  Search News Releases

     

 

EurekAlert!